Overview
- Goldman Sachs cut its Oklo price target to $65 and kept a Neutral rating.
- The bank cited higher operating costs and a 2026 spending plan of $350 million to $450 million, even as liquidity rose to about $2.6 billion after recent fundraises.
- DOE approved the Nuclear Safety Design Agreement for Atomic Alchemy’s Groves test reactor in Texas, moving the project into the next safety review phase under the federal pilot program.
- Oklo closed its $25 million purchase of Atomic Alchemy to build near-term U.S. isotope supply, with initial production planned this year and initial reactor startup targeted in 2026.
- High-grade isotopes are scarce, so new domestic output could speed cancer diagnostics and treatment, support advanced manufacturing and research, and reduce reliance on overseas sources.